Gains for tech stocks push Nasdaq to another record

A rally in big tech stocks led the broader market to a higher close Wednesday, lifting the Nasdaq to an all-time high and helping Wall Street claw back most of its losses from earlier in the week.

The S&P 500 rose 0.6% for its first gain this week. The benchmark index remains near the record it set last week after a better-than-expected U.S. jobs report.

The Dow Jones Industrial Average added 0.5%. The Nasdaq composite, which is heavily weighted with technology stocks, closed 0.9% higher. The gain was good enough to nudge the index past the record high it set last Thursday.

Nvidia rose 1.8% and became the first public company to exceed $4 trillion in value after its share price briefly topped $164 each in the early going. Shares in the AI boom poster child were going for around $14 per share at the start of 2023.

The tech rally came as Wall Street continued to weigh the latest developments in President Trump’s renewed push this week to use threats of higher tariffs on goods imported into the U.S. in hopes of securing new trade agreements with countries around the globe.

Wednesday was initially set as a deadline by Trump for countries to make deals with the U.S. or face heavy increases in tariffs. But with just two trade deals announced since April, one with the United Kingdom and one with Vietnam, the window for negotiations has been extended to Aug. 1.

This latest phase in the White House’s trade war heightens the threat of potentially more severe tariffs that’s been hanging over the global economy. Higher taxes on imported goods could hinder economic growth, if not increase recession risks.

On Tuesday, Trump said he would be announcing tariffs on pharmaceutical drugs at a “very, very high rate, like 200%.” He also said he would sign an executive order placing a 50% tariff on copper imports, matching the rates charged on steel and aluminum.

Copper prices eased Wednesday after spiking a day earlier. Shares in mining company Freeport-McMoRan fell 1.5%.

Financial markets swooned from day to day for weeks after the White House rolled out its proposed tariff hikes in the spring. With the new batch of U.S. taxes on imports not set to kick in until next month, that gives Wall Street a breather just as the next corporate earnings season is set to begin.

“I think most people are tired of tariff news and they’re starting to realize it just doesn’t matter much,” said Jay Hatfield, CEO of Infrastructure Capital Advisors. “We’re pretty bullish about earnings. I think the rest of the market is too.”

Wall Street analysts predict that companies in the S&P 500 will deliver a combined 5% annual growth in second-quarter earnings, according to FactSet. That would mark the lowest growth rate for the index since the fourth quarter of 2023.

Delta Air Lines kicks off earnings season on Thursday, with most analysts expecting the airline’s second-quarter profit to decline from a year ago. Delta and other major U.S. carriers have trimmed their flight schedules and pulled their forecasts this year as consumers pull back on travel and other nonessential spending due to uncertainty about how Trump’s tariffs will affect their budgets.

Gains in technology and communication services stocks outweighed declines in energy and other sectors Wednesday.

Microsoft rose 1.4%, Meta gained 1.7% and Google parent Alphabet added 1.3%.

Amazon rose 1.4% a day after the online retail giant kicked off Prime Day, extending it for the first time to four days.

All told, the S&P 500 rose 37.74 to 6,263.26. The Dow added 217.54 to 44,458.30, and the Nasdaq gained 192.87 to close at 20,611.34.

In bond market trading, the yield on the 10-year Treasury slid to 4.34% from 4.40% late Tuesday.

In overseas markets, stock indexes closed broadly higher in Europe after a mixed finish in Asia.

Outside of trade talks, some corporate news surfaced Wednesday after a typically quiet early summer stretch.

Pharmaceutical giant Merck is buying Verona Pharma, a U.K. company that focuses on respiratory diseases, in an approximately $10-billion deal. If approved by Verona shareholders and U.K. officials, Merck will get access to Verona’s chronic obstructive pulmonary disease medication Ohtuvayre. Verona shares jumped 20.6% on the news, while Merck shares rose 2.9%.

Veiga writes for the Associated Press.